Molecular Genetics of Multiple Myeloma

CL Bi, National University of Singapore, Singapore
WJ Chng, National University of Singapore, Singapore

Published online: September 2010

DOI: 10.1002/9780470015902.a0022446

Multiple myeloma (MM) is the second most common haematologic malignancy causing significant mortality and morbidity. The initial malignant clone undergoes multistep transformation, which could results from genetic and epigenetic deregulation, the acquisition of clonogenic properties and also abnormal interaction with tumour microenvironment. Two patterns of primary genetic events have been described: recurrent translocations involving the immunoglobulin heavy chain (IgH) locus and hyperdiploid characterised by chromosomal trisomies. Besides playing an important role in disease pathogenesis, these genetic abnormalities also have important prognostic impact. Further, the genes and pathways dysregulated in high-risk disease can be used to develop specific therapeutic strategies. In this article, we concentrate on molecular pathways deregulated by genetic and epigenetic abnormalities, and their potential biological and clinical implications.

Key Concepts:

  • All multiple myeloma have a preceeding premalignant monoclonal gammopathy of undetermined significance phase.
  • Two dichotomous pathways are involved in disease initiation: translocations involving the immunoglobulin heavy chain and hyperdiploidy involving recurrent trisomies in chromosomes 3, 5, 7, 9, 11, 15 and 19.
  • All primary disease-causing events lead to universal overexpression of one or more cyclin D gene.
  • MYC activation or reduction of retinoblastoma gene functions may be involved in disease transformation.
  • Additional mutations affecting the nuclear factor kappaB and p53 pathways may lead to independence from stromal environment leading to disease progression.
  • Genetic abnormalities are powerful prognostic factors in myeloma and can be used to define patients with high-risk disease.
  • Certain novel therapeutic agents can overcome the poor prognosis of cytogenetics. As such, risk stratification in the treatment of myeloma is a possibility.

Keywords: myeloma; cytogenetics; fluorescence in situ hybridisation; microRNA; epigenetics; translocations; prognosis; nuclear factor kappaB; cyclin D; P53 pathways

 References
    Avet-Loiseau H (2007) Role of genetics in prognostication in myeloma. Best Practice & Research. Clinical Haematology 20: 625–635.
    Avet-Loiseau H, Attal M, Moreau P et al. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109: 3489–3495.
    Bergsagel PL, Chesi M, Nardini E et al. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings of the National Academy of Sciences of the USA 93: 13931–13936.
    Bergsagel PL, Kuehl WM, Zhan F et al. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106: 296–303.
    Bild AH, Yao G, Chang JT et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357.
    Calin GA, Dumitru CD, Shimizu M et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the USA 99: 15524–15529.
    Chang H, Trieu Y, Qi X et al. (2007) Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research 31: 779–782.
    Chesi M, Robbiani DF, Sebag M et al. (2008) AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13: 167–180.
    Chim CS, Kwong YL and Liang R (2008) Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clinical Lymphoma & Myeloma 8: 331–339.
    Chng WJ, Braggio E, Mulligan G et al. (2008) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 111: 1603–1609.
    Chng WJ, Gertz MA, Chung TH et al. (2010) Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 24: 833–842.
    Chng WJ, Glebov O, Bergsagel PL and Kuehl WM (2007a) Genetic events in the pathogenesis of multiple myeloma. Best Practice & Research. Clinical Haematology 20: 571–596.
    Chng WJ, Mulligan G, Bryant B and Bergsagel L (2007b) Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events. Blood 109: 3610–3611.
    Chng WJ, Price-Troska T, Gonzalez-Paz N et al. (2007c) Clinical significance of TP53 mutation in myeloma. Leukemia 21: 582–584.
    Chng WJ, Van Wier SA, Ahmann GJ et al. (2005) A validated FISH trisomy index demonstrates the hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood 106: 2156–2161.
    Demchenko YN, Glebov OK, Zingone A et al. (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115: 3541–3552.
    Dib A, Peterson TR, Raducha-Grace L et al. (2006) Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Division 1: 23.
    Dispenzieri A, Rajkumar SV, Gertz MA et al. (2007) Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clinic Proceedings 82: 323–341.
    Fonseca R, Barlogie B, Bataille R et al. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research 64: 1546–1558.
    Greipp PR, San Miguel J, Durie BG et al. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology 23: 3412–3420.
    Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I et al. (2010) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 24: 629–637.
    van Haaften G, Dalgliesh GL, Davies H et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics 41: 521–523.
    Iorio MV and Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. Journal of Clinical Oncology 27: 5848–5856.
    Jemal A, Siegel R, Ward E et al. (2007) Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57: 43–66.
    Kapoor P, Kumar S, Fonseca R et al. (2009) Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114: 518–521.
    Keats JJ, Fonseca R, Chesi M et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131–144.
    Keats JJ, Reiman T, Belch AR and Pilarski LM (2006) Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leukemia & Lymphoma 47: 2289–2300.
    Kuppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews. Cancer 5: 251–262.
    Kyle RA, Remstein ED, Therneau TM et al. (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New England Journal of Medicine 356: 2582–2590.
    Kyle RA, Therneau TM, Rajkumar SV et al. (2006) Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine 354: 1362–1369.
    Landgren O and Weiss BM (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23: 1691–1697.
    Leone PE, Walker BA, Jenner MW et al. (2008) Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clinical Cancer Research 14: 6033–6041.
    Lionetti M, Agnelli L, Mosca L et al. (2009a) Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 48: 521–531.
    Lionetti M, Biasiolo M, Agnelli L et al. (2009b) Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114: e20–26.
    Loffler D, Brocke-Heidrich K, Pfeifer G et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110: 1330–1333.
    Marango J, Shimoyama M, Nishio H et al. (2008) The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111: 3145–3154.
    Mulligan G, Mitsiades C, Bryant B et al. (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109: 3177–3188.
    Pichiorri F, Suh SS, Ladetto M et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the USA 105: 12885–12890.
    Potti A, Dressman HK, Bild A et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nature Medicine 12: 1294–1300.
    Reece D, Song KW, Fu T et al. (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114: 522–525.
    Roccaro AM, Sacco A, Thompson B et al. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113: 6669–6680.
    Roman-Gomez J, Agirre X, Jimenez-Velasco A et al. (2009) Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. Journal of Clinical Oncology 27: 1316–1322.
    Ronchetti D, Lionetti M, Mosca L et al. (2008) An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Medical Genomics 1: 37.
    San Miguel JF, Schlag R, Khuageva NK et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine 359: 906–917.
    Shaughnessy JD Jr, Zhan F, Burington BE et al. (2006) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109: 2276–2284.
    Wuilleme S, Robillard N, Lode L et al. (2004) Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia.
    Xiong W, Wu X, Starnes S et al. (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112: 4235–4246.
    Zhou Y, Barlogie B and Shaughnessy JD Jr (2009) The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 23: 1941–1956.
    Zhou Y, Chen L, Barlogie B et al. (2010) High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proceedings of the National Academy of Sciences of the USA 107: 7904–7909.
 Further Reading
    Bergsagel PL and Kuehl WM (2001) Chromosome translocations in multiple myeloma. Oncogene 20: 5611–5622.
    Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nature Reviews. Genetics 10: 704–714.
    Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews. Cancer 7: 585–598.
    Jones PA and Baylin SB (2007) The epigenomics of cancer. Cell 128: 683–692.
    Kuehl WM and Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews. Cancer 2: 175–187.
    Ocio EM, Mateos MV, Maiso P, Pandiella A and San-Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncology 9: 1157–1165.
    Podar K, Chauhan D and Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23: 10–24.
    San-Miguel J, Harousseau JL, Joshua D and Anderson KC (2008) Individualizing treatment of patients with myeloma in the era of novel agents. Journal of Clinical Oncology 26: 2761–2766.

Related Sub-Topics:

Tumour Immunology | Intracellular and Extracellular Signalling | Cell Biology of Cancer | Molecular Genetics of Common and Complex Disease | Cancer Genetics | Epigenetics and Disease
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Molecular Genetics of Multiple Myeloma
 
How to Cite close
Bi, CL, and Chng, WJ(Sep 2010) Molecular Genetics of Multiple Myeloma. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0022446]